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Abstract
Introduction Long-acting muscarinic antagonists confer
improvements in spirometry when used in addition to
inhaled corticosteroids and long-acting beta-agonists (ICS/
LABA) in COPD. The dual objectives of this proof of
concept study were to evaluate trough effects of tiotropium
(TIO) or aclidinium (ACL) when used as triple therapy and
to assess if impulse oscillometry (IOS) might be more
sensitive than spirometry in detecting subtle differences in
bronchodilator response.
Methods Patients with moderate to severe COPD already
taking ICS/LABA were randomized to receive add-on
therapy in cross-over fashion with either TIO 18 lg od or
ACL 322 lg bid for 2–3 weeks each. Measurements of
IOS, spirometry, 6-min walk test, St George’s Respiratory
Questionnaire (SGRQ) and Baseline/Transition Dyspnoea
Index (TDI) were made at baseline and after chronic dosing
at trough (12 h for ACL and 24 h for TIO), in addition to
domiciliary diurnal spirometry.
Results 13 patients were completed: mean age 69 years,
FEV1 52 % predicted, FEV1/FVC 0.48, and R5 202 %
predicted. There were no differences in any visit-based
trough IOS or spirometry outcomes comparing TIO versus
ACL. Resonant frequency but not total airway resistance at
5 Hz (R5) significantly improved from baseline with both
treatments while peripheral airway resistance (R5–R20)
significantly improved with ACL. Visit-based FEV1, and
forced and relaxed vital capacity were also significantly
improved from baseline with both treatments. There were
no significant differences in diurnal FEV1 and FEV6 pro-
files between treatments. 6-min walk distance and post-
walk fatigue significantly improved from baseline with
ACL, while post-walk dyspnea improved with TIO. SGRQ
symptom score significantly improved to a similar degree
with both treatments. TDI significantly improved with
ACL versus TIO by 1.54 units.
Conclusion We observed comparable bronchodilator effi-
cacy at trough with TIO and ACL when used as triple therapy
in COPD, while IOS was no more sensitive than spirometry.
Keywords COPD  Spirometry  Impulse oscillometry 
Tiotropium  Aclidinium
Introduction
Long-acting muscarinic antagonists (LAMA) are recom-
mended in chronic obstructive pulmonary disease man-
agement guidelines [1] as bronchodilator therapy either
alone or in combination with long-acting beta-agonists
(LABA) and inhaled corticosteroids (ICS). Currently
available LAMA include once daily tiotropium (TIO),
glycopyrronium (GLYC) and umeclidinium or twice daily
aclidinium (ACL). ACL and TIO have similar binding
affinities for the M3 receptor and comparable kinetic
selectivity for M3 over M2 receptors, while the duration of
action for TIO is approximately two-fold longer than that
for ACL [2]. For patients with more severe COPD the use
of triple therapy with ICS/LABA/LAMA is advocated to
improve outcomes including pulmonary function, quality
of life, and exacerbations [3–9].
Few studies have however compared different LAMA
when used as triple therapy. Once daily use of TIO or
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glycopyrronium versus placebo for 12 weeks as add-on
therapy to ICS/LABA conferred similar improvements in
spirometry and quality of life in patients with moderate to
severe COPD [10]. In a chronic dosing comparison of once
daily TIO and twice daily ACL as monotherapy for 2 weeks,
the diurnal bronchodilator profile showed a noticeable
decline in forced expiratory volume in 1 s (FEV1) between
12 and 24 h with TIO along with an improvement with ACL
after the second evening dose over the same time period,
such that the difference was significant [11]. In another
study comparing TIO and ACL as monotherapy for
6 weeks, there were similar significant improvements in the
24 h FEV1 profile with both drugs compared with placebo,
while only ACL significantly reduced early morning cough,
wheeze, dyspnea, phlegm, and nighttime symptoms versus
placebo [12]. In both of these studies [11, 12] there was no
significant difference in morning pre dose trough FEV1
when comparing ACL and TIO after chronic dosing.
Spirometry involves a forced expiratory maneuver which
may not be the ideal test to detect subtle improvements in
airway caliber in COPD due to effort-dependent small air-
way closure. Impulse oscillometry (IOS) is an effort-inde-
pendent test performed during normal quiet breathing,
thereby obviating expiratory small airway closure [13]. IOS
is easier to perform for patients with COPD during tidal
breathing and measures the frequency dependence of air-
way resistance (R) and reactance (X). As previously
described [13], IOS can be used to derive total airway
resistance at 5 Hz (R5), central airway resistance at 20 Hz
(R20), peripheral resistance (R5–R20), reactance at 5 Hz
(X5), and area under the reactance curve (AX) as well as the
resonant frequency (RF). In one study using IOS comparing
TIO and placebo as add-on to ICS/LABA, there was no
significant additive improvement on IOS outcomes with
chronic dosing, despite a significant improvement in FEV1
[9]. However, we are not aware of any studies which have
compared different LAMA as triple therapy using IOS.
The dual objectives of this proof of concept study were to
evaluate the effects of TIO or ACL at trough when used as
add-on therapy to pre-existing ICS/LABA and also to assess
whether impulse oscillometry (IOS) might be more sensitive
than spirometry in detecting subtle differences in bron-
chodilator efficacy. We also used domiciliary spirometry
measurements to follow diurnal changes in airway caliber at
steady state during each randomized treatment period.
Methods
Study Participants
Inclusion criteria were male or female volunteers aged
40–80 years with moderate to severe COPD on ICS/
LABA, FEV1 30–80 % and smoking history C10 pack-
years. Exclusion criteria were other significant respiratory
diseases; a COPD exacerbation or respiratory tract infec-
tion requiring systemic steroids, and/or antibiotics within
1 month (3 months if hospitalization was required) of the
study commencement. The East of Scotland Research
Ethics Service granted ethical approval (Ref: 13/ES/0122),
and all patients provided written informed consent.
Study Design
We carried out a randomized, open-label, cross-over study
(Fig. 1). Previously prescribed LAMA were stopped at the
screening visit. After a 1- to 2-week period on ICS/LABA,
patients were randomized to either ACL (Eklira Genuair,
Astra Zeneca, Luton, UK) 322 lg bid or TIO (Spiriva
HandiHaler, Boehringer, Bracknell, UK) 18 lg bid. Fol-
lowing the run-in period, at visit 1, baseline measurements
were recorded. After 2–3 weeks on the study inhaler, par-
ticipants returned to the department for visit 2. All mea-
surements were taken at trough (i.e., 12 h post dose for ACL
and ICS/LABA and 24 h post dose for TIO). Participants
attended the department the same time during each study
visit. After the first treatment period, participants entered a
wash-out period of 1–2 weeks. The same process was
repeated with the other study inhaler after cross-over.
Primary and Secondary Outcomes
The primary outcome was change in trough R5 from
baseline after chronic dosing. Secondary outcomes inclu-
ded change from baseline in the remaining IOS variables
(R20, R5–R20, X5, RF and AX), spirometry including
FEV1, forced mid-expiratory flow between 25 and 75 % of
forced vital capacity (FEF25–75), forced vital capacity
(FVC), relaxed vital capacity (RVC), 6-min walk test
(6MWT), domiciliary PiKo-6 measurements for FEV1 and
FEV6, St George’s Respiratory Questionnaire (SGRQ) and
Baseline/Transition Dyspnoea Index (BDI-TDI).
Measurements
Impulse oscillometry (Masterscreen IOS, Ho¨chberg, Ger-
many) was performed in triplicate according to the manu-
facturer’s instructions. Spirometry was performed using a
SuperSpiro (Micro Medical Ltd, Chatham, Kent, UK).
Domiciliary FEV1 & FEV6 measurements were recorded
using a handheld PiKo-6 monitor (n-Spire Health, Long-
mont, CO, USA). Domiciliary PiKo-6 measurements were
recorded at trough for both drugs; and after each morning
and evening dose of ACL (i.e., 2 h post dose); or at cor-
responding times after each morning dose of TIO (i.e., 2
and 14 h post dose).
260 Lung (2016) 194:259–266
123
Statistical Analysis
The study was powered at 80 % to detect a 0.1 kPa L-1 s
difference in the primary outcome of trough R5, assuming
a within subject standard deviation of 0.13 kPa L-1 s, and
an alpha error of 0.05 (two-tailed). Data were first exam-
ined for normality of distribution. Paired Students t-tests
were used to compare between treatment effects at either
baseline and after each chronic dosing, as well as within
treatment effects comparing baseline versus chronic dos-
ing. Repeated measures analysis of variance was used to
assess the diurnal profile from serial domiciliary FEV1 and
FEV6 measurements using the average from the last week
of each randomized treatment period and the last week of
each baseline.
Results
Thirteen patients were completed per protocol (Fig. 2): age
69 years, 10 males, and mean of 47 pack-years. Post-
bronchodilator FEV1 was 52 % predicted with 10 %
reversibility, FEV1/FVC ratio was 0.48, and R5 % was
202 % predicted. Nine patients were taking fluticasone/
salmeterol, 3 budesonide/formoterol, and 1 beclometha-
sone/formoterol, with a mean beclomethasone equivalent
dose of 1000 lg day-1. 11 patients were taking LAMA: 8
with TIO, 2 with ACL, and 1 with glycopyrronium.
Baseline values prior to randomized treatments were not
significantly different, and there were also no significant
differences in baselines according to visit sequence. There
were no differences in any visit-based trough IOS or
spirometry outcomes comparing TIO versus ACL (Table 1;
Fig. 3). Resonant frequency (RF) but not total airway
resistance at 5 Hz (R5) significantly improved from base-
line within both treatments, while peripheral airway resis-
tance (R5–R20) significantly improved with ACL
(Tables 2, 3). Visit-based FEV1, FVC, and RVC were also
significantly improved from baseline within both treat-
ments (Tables 2, 3). There were no significant differences
between treatments at any time points during the diurnal
FEV1 and FEV6 profiles (Fig. 4).
Fig. 1 After a 1- to 2-week run-in, patients received either tiotropium 18 lg od or aclidinium 322 lg bid for 2–3 weeks each with a 1- to 2-week
wash-out in between. Baseline values were measured at Visit 1/3 and after chronic dosing at Visit 2/4
Fig. 2 CONSORT diagram showing the flow of participants through
the study
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There were no significant differences between treatments
for the 6-min walk test (Table 1). Six-min walk distance and
post-walk fatigue significantly improved from baseline with
ACL, while post-walk dyspnea improved with TIO
(Tables 2, 3). Post-walk heart rate and oxygen saturation
were not significantly altered by either treatment (Fig. 5).
SGRQ symptom score significantly improved with both
drugs from baseline, but there was no difference between
treatments total or symptoms score (Tables 1, 2, 3). Mean
BDI was 6.54, while TDI was significantly improved by
ACL (1.0) versus TIO (–0.54): mean difference 1.54 (95 %
CI 0.39–2.69), P = 0.013.
Discussion
The results of this proof of concept study showed no sig-
nificant differences between randomized treatments in any
IOS or spirometry outcomes measured at trough after
chronic dosing with TIO and ACL when used as triple
therapy in patients with COPD. We found no significant
difference between treatments in the primary outcome of
R5, although neither drug produced any significant
improvements in R5 from baseline. Within the power
constraints of the sample size, we cannot exclude the
possibility that we may have missed a difference in R5
smaller than 0.1 kPa L-1 s, which we considered to be a
clinically important difference. Other IOS outcomes
including R20, X5, and AX were not significantly
improved from baseline with either drug from baseline.
Nonetheless, we showed that both treatments produced
comparable significant improvements from baseline in RF,
while ACL also produced a significant improvement in
R5–R20. However, the clinical relevance of small changes
in IOS outcomes in COPD is uncertain as there are cur-
rently no published data with regard to minimal important
differences. In one cross-sectional study in COPD patients,
peripheral airway resistance correlated with FEV1 and
FEF25–75 but not with the Medical Research Council
(MRC) dyspnea score [14]. In a baseline cross-sectional
analysis of the ECLIPSE study in COPD, IOS was found to
be reproducible and was able to define the severity of
disease according to global initiative for chronic obstruc-
tive lung disease (GOLD) status [15].
Table 1 Change from baseline
for aclidinium versus tiotropium
Parameter Aclidinium Tiotropium Difference (95 % CI) P value
FEV1(L) 0.11 0.15 -0.04 (-0.13, 0.05) 0.36
FVC (L) 0.28 0.24 0.03 (-0.16, 0.23) 0.72
FEF25–75 (L s
-1) 0.02 0.06 -0.04 (-0.10, 0.01) 0.13
RVC (L) 0.30 0.22 0.08 (-0.12, 0.28) 0.39
RVC/FVC 0.01 -0.05 0.06 (-0.09, 0.21) 0.38
R5 (kPa L-1 s) -0.07 -0.03 -0.04 (-0.12, 0.04) 0.29
R20 (kPa L-1 s) -0.01 -0.02 0.01 (-0.05, 0.06) 0.80
R5–R20 (kPa L-1 s) -0.06 -0.01 -0.05 (-0.11, 0.02) 0.13
X5 (kPa L-1 s) 0.03 0.05 -0.02 (-0.09, 0.06) 0.62
RF (Hz) -2.22 -2.77 0.54 (-2.90, 3.99) 0.74
AX (kPa L-1) -0.70 -0.55 -0.15 (-0.84, 0.54) 0.65
6MWT
Distance (m) 36 9 27 (-2, 56) 0.07
Post-walk oxygen saturation (%) 0 0 0 (-2, 2) 0.93
Post-walk heart rate (bpm) 3 1 2 (-2, 6) 0.36
Post-walk dyspnoea (Borg scale) -0.6 -0.7 0.1 (-0.6, 0.7) 0.79
Post-walk fatigue (Borg scale) -0.5 -0.3 -0.2 (-0.6, 0.2) 0.34
SGRQ
Symptoms score -7.35 -7.31 -0.03 (-5.66, 5.59) 0.99
Total score -0.97 -2.35 1.38 (-1.85, 4.61) 0.37
Mean values for change from baseline are shown each drug as well as the difference between the drugs
FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, FEF25–75 forced mid-expiratory flow
between 25 and 75 % of forced vital capacity, RVC relaxed vital capacity, R5 total airway resistance at
5 Hz, R20 central airway resistance at 20 Hz, R5–R20 peripheral airway resistance as the difference
between 5 Hz and 20 Hz, RF resonant frequency, X5 reactance at 5 Hz, AX reactance area, 6MWT 6-min
walk test, bpm beats per minute, SGRQ St George’s Respiratory Questionnaire
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We are aware of only one other clinical trial evaluating
triple therapy in COPD using IOS. In that study, Wil-
liamson et al. enrolled patients with severe COPD (FEV1
42 %) comparing 2 weeks of TIO and placebo as add-on to
ICS/LABA [9]. IOS outcomes including R5, R20, and X5
were not significantly different after 2 weeks of treatment
despite a significant improvement in FEV1. This disconnect
between improvements in FEV1 but not R5 in response to
TIO after 2 weeks is consistent with our current findings.
Moreover, the mean R5 at baseline on ICS/LABA prior to
TIO reported by Williamson et al. was 0.7 kPa L-1 s
which is similar to baseline R5 values in our patients.
Fig. 3 Effects on impulse oscillometry outcomes at baseline and
post-treatment with either tiotropium or aclidinium. Data are depicted
for individuals as well as means and SEM. a R5 total airway
resistance b R5–R20 peripheral airway resistance c RF resonant
frequency. There were significant improvements from baseline in RF
with aclidinium (P\ 0.05) and tiotropium (P\ 0.01), and in R5–20
with tiotropium (P\ 0.05). There were no significant differences
between tiotropium and aclidinium in any oscillometry outcomes
Table 2 Within aclidinium:
baseline versus post-treatment
Parameter Baseline Post-aclidinium Difference (95 % CI) P value
FEV1 (L) 1.21 1.32 0.11 (0.03, 0.18) 0.009
FVC (L) 2.67 2.95 0.28 (0.05, 0.50) 0.02
FEF25–75 (L s-1) 0.46 0.48 0.02 (-0.04, 0.08) 0.50
RVC (L) 3.12 3.43 0.30 (0.19, 0.42) \0.0001
RVC/FVC 1.17 1.18 0.01 (-0.08, 0.10) 0.76
R5 (kPa L-1 s) 0.78 0.71 -0.07 (-0.15, 0.01) 0.07
R20 (kPa L-1 s) 0.42 0.41 -0.01 (-0.04, 0.03) 0.61
R5–R20 (kPa L-1 s) 0.35 0.29 -0.06 (-0.11, -0.01) 0.02
X5 (kPa L-1 s) -0.38 -0.34 0.03 (-0.04, 0.11) 0.36
RF (Hz) 28.54 26.32 -2.22 (-4.37, -0.08) 0.04
AX (kPa L-1) 4.29 3.58 -0.71 (-1.49, 0.07) 0.07
6MWT
Distance (m) 406 442 36 (1, 70) 0.045
Post-walk oxygen saturation (%) 91 92 0 (-2, 2) 0.73
Post-walk heart rate (bpm) 76 79 3 (0, 6) 0.08
Post-walk dyspnoea (Borg scale) 2.7 2.2 -0.6 (-1.2, 0.1) 0.08
Post-walk fatigue (Borg scale) 2.2 1.7 -0.5 (-1.0, 0.0) 0.04
SGRQ
Symptoms score 45.10 37.76 -7.35 (-14.12, -0.57) 0.04
Total score 36.75 35.78 -0.97 (-4.51, 2.57) 0.56
Mean values are shown
FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, FEF25–75 forced mid-expiratory flow
between 25 and 75 % of forced vital capacity, RVC relaxed vital capacity, R5 total airway resistance at
5 Hz, R20 central airway resistance at 20 Hz, R5–R20 peripheral airway resistance as the difference
between 5 Hz and 20 Hz, RF resonant frequency, X5 reactance at 5 Hz, AX reactance area, 6MWT 6-min
walk test, bpm beats per minute, SGRQ St George’s Respiratory Questionnaire
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Perhaps performing a further evaluation using a full 24-h
profile with serial IOS as an area under the curve (AUC)
might be able to detect more subtle differences in airway
caliber which we did not observe on a single trough
measurement.
Whole-body plethysmography is alternative effort-in-
dependent test using a panting maneuver which can mea-
sure airway resistance (or its reciprocal as conductance) but
is more difficult and time consuming to perform than IOS.
Singh et al. reported on a comparison of fluticasone/
Table 3 Within tiotropium:
baseline versus post-treatment
Parameter Baseline Post-tiotropium Difference (95 % CI) P value
FEV1 (L) 1.20 1.35 0.15 (0.10, 0.20) \0.0001
FVC (L) 2.73 2.97 0.24 (0.10, 0.39) 0.003
FEF25–75 (L s-1) 0.47 0.53 0.06 (0.02, 0.10) 0.004
RVC (L) 3.22 3.44 0.22 (0.04, 0.41) 0.02
RVC/FVC 1.23 1.18 -0.05 (-0.16, 0.06) 0.32
R5 (kPa L-1 s) 0.74 0.71 -0.03 (-0.09, 0.03) 0.30
R20 (kPa L-1 s) 0.42 0.41 -0.01 (-0.04, 0.02) 0.36
R5–R20 (kPa L-1 s) 0.31 0.30 -0.01 (-0.07, 0.04) 0.58
X5 (kPa L-1 s) -0.37 -0.33 0.05 (-0.01, 0.11) 0.12
RF (Hz) 28.90 26.13 -2.77 (-4.58, -0.96) 0.006
AX (kPa L-1) 4.21 3.66 -0.55 (-1.16, 0.05) 0.07
6MWT
Distance (m) 429 437 9 (-13, 30) 0.40
Post-walk oxygen saturation (%) 92 93 0 (-1, 2) 0.64
Post-walk heart rate (bpm) 75 76 1 (-2, 4) 0.49
Post-walk dyspnoea (Borg scale) 2.8 2.1 -0.7 (-1.2, -0.1) 0.03
Post-walk fatigue (Borg scale) 2.4 2.1 -0.3 (-0.8, 0.2) 0.21
SGRQ
Symptoms score 47.34 40.03 -7.31 (-14.62, 0.00) 0.05
Total score 38.85 36.50 -2.35 (-5.71, 1.02) 0.15
Mean values are shown
FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, FEF25–75 forced mid-expiratory flow
between 25 and 75 % of forced vital capacity, RVC relaxed vital capacity, R5 total airway resistance at
5 Hz, R20 central airway resistance at 20 Hz, R5–R20 peripheral airway resistance as the difference
between 5 Hz and 20 Hz, RF resonant frequency, X5 reactance at 5 Hz, AX reactance area, 6MWT 6-min
walk test, bpm beats per minute, SGRQ St George’s Respiratory Questionnaire
Fig. 4 Effects on spirometry outcomes at baseline and post-treatment
with either tiotropium or aclidinium. Data are depicted for individuals
as well as means and SEM. a FEV1 forced expiratory volume in 1 s
b FVC forced vital capacity c RVC relaxed vital capacity. There were
significant improvements from baseline for FEV1 within aclidinium
(P\ 0.01) and tiotropium (P\ 0.0001), for FVC within aclidinium
(P\ 0.05) and tiotropium (P\ 0.01), and for RVC within aclidinium
(P\ 0.0001) and tiotropium (P\ 0.05). There were no significant
differences between tiotropium and aclidinium in any spirometry
outcomes
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salmeterol versus fluticasone/salmeterol/TIO for 2 weeks
in patients with COPD, where the primary outcome of peak
specific airway conductance (as AUC 0–4 h) showed a
27 % significant difference in favor of triple therapy, while
for trough FEV1, there was a significant mean difference of
110 ml [3]. In our study, we showed significant within
treatment improvements in mean trough FEV1 amounting
to 110 ml with ACL and 150 ml with TIO, as compared to
the minimal important difference of 100–140 ml [16] .
For visit-based spirometry outcomes including FEV1,
FVC, and RVC we observed significant within treatment
effects compared to baseline in response to TIO and ACL,
but no difference between treatments. Moreover, there
were no significant differences between treatments for
domiciliary diurnal profiles of FEV1 and FEV6. In a pre-
vious comparison of the same doses of TIO and ACL used
as monotherapy, there were no differences between drugs
in terms of trough pre-dose FEV1 measurements after
2 weeks, although the AUC 12–24 h for the visit-based
diurnal FEV1 profile was significantly better with ACL
compared to TIO after chronic dosing [11]. This observed
difference in the FEV1 AUC 12–24 h corresponds to the
12-h period after taking the evening dose of ACL when the
effect of TIO is beginning to wane throughout the night
time prior to the next morning dose. Perhaps on reflection,
we might have also shown such differences in domiciliary
FEV1 if we had performed diurnal evening measurements
between the 14- and 24-h time point for TIO, although we
considered that this was not practical for elderly patients to
perform at home. Another possibility is that in the present
study, there may be less room for further improvement
conferred by LAMA when given as add-on to ICS/LABA
compared to its use as monotherapy. In a previous com-
parison of TIO and GLYC as add-on to ICS/LABA, the
mean difference in the primary outcome of trough FEV1
amounted to 7 ml [10], as compared to a 40 ml difference
between TIO and ACL in the present study.
We used dry powder formulations of TIO and ACL
which emit coarse particles [2 lm, which could also
explain the somewhat limited improvements in pulmonary
function. In this regard, we are not aware of any head to
head lung deposition studies comparing TIO and ACL dry
powder formulations in COPD. Perhaps using smaller
particle formulations such as the fine-mist TIO Respimat
inhaler might result in greater improvements in regional
lung deposition.
With the development of single inhaler triple therapy, it
will be important to know what the impact is on more
clinically relevant outcomes. In a retrospective cohort
study of 2853 patients with moderate to severe COPD
followed up over 4.65 years, there were 996 receiving ICS/
LABA (FEV1 of 63 %) and 1857 receiving ICS/LABA/
LAMA (FEV1 of 51 %) [17]. Comparing triple versus dual
therapy, there was a 15 % reduction in hospital admissions,
29 % fewer oral corticosteroid bursts, and 26 % lower all-
cause mortality, while triple therapy was associated with a
fall in serial FEV1 of 30 ml over 4 years.
Aside from pulmonary function outcomes, it is also
important to consider the impact of treatment upon func-
tional status (6-min walk distance and dyspnoea index) and
health-related quality of life (SGRQ) [16]. While we
observed no difference between treatments in 6-min
walking distance, there was a 36 m mean improvement
from baseline with ACL, which exceeds the minimal
important difference of 25 m [18, 19]. There was a sig-
nificant improvement post-walk fatigue with ACL and in
post-walk dyspnoea with TIO, but no differences were seen
in either outcome between treatments. Furthermore post-
Fig. 5 Diurnal profiles with either tiotropium given once daily in the
morning or aclidinium given twice daily in the morning and evening,
for the last week of each randomized treatment. Data are depicted as
means and SEM. a FEV1 forced expiratory volume in 1 s b FEV6
forced expiratory volume in 6 s. Data are shown for the morning
trough measurement (i.e., pre-dose for aclidinium and tiotropium), 2
and 12 h post dose (i.e., trough for aclidinium), and 2 h post the
evening dose of aclidinium or 14 h after the morning dose of
tiotropium. There were no significant differences between tiotropium
and aclidinium at any time points
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walk heart rate and oxygen saturation did not change with
either treatment. In terms of quality of life, although the
SGRQ symptoms score was significantly improved with
both drugs, there was no difference between them. The
transition dyspnoea index was significantly improved by
ACL versus TIO by a mean difference of 1.54 which
exceeded the minimal important difference of 1.0 [20]. The
relevance of this finding in the absence of any differences
in objective pulmonary function outcomes is uncertain.
In summary, we observed comparable bronchodilator
efficacy at trough with TIO and ACL when used as triple
therapy in COPD, while IOS was no more sensitive than
spirometry. The utility of IOS measurements in COPD
requires further evaluation perhaps using a diurnal IOS
profile to compare with spirometry or whole-body
plethysmography.
Acknowledgments We would like to thank Almirall for the unre-
stricted grant and supply of the ACL inhalers.
Funding This study was funded by an unrestricted grant from
Almirall. Almirall did not have any role in the study design; in the
collection, analysis and interpretation of data; in the writing of the
report; and in the decision to submit the article for publication.
Compliance with Ethical Standards
Conflicts of interest The Scottish Centre for Respiratory Research
has received an unrestricted Grant from Almirall to support the pre-
sent study and from AstraZeneca for recruiting into a multicentre
trial. BJL has received payments from Boehringer for consulting and
attending advisory boards as well as support for attending the British
Thoracic Society and European Respiratory Society and American
Academy of Allergy Asthma and Immunology. AM and AEM have
no conflicts of interest to declare.
Ethical Standards This manuscript complies with the current laws
of the United Kingdom
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Vestbo J, Hurd SS, Agusti AG et al (2013) Global strategy for the
diagnosis, management, and prevention of chronic obstructive
pulmonary disease: GOLD executive summary. Am J Respir Crit
Care Med 187(4):347–365
2. Gavalda A, Ramos I, Carcasona C et al (2014) The in vitro and
in vivo profile of aclidinium bromide in comparison with gly-
copyrronium bromide. Pulm Pharmacol Ther 28(2):114–121
3. Singh D, Brooks J, Hagan G, Cahn A, O’Connor BJ (2008)
Superiority of ‘‘triple’’ therapy with salmeterol/fluticasone pro-
pionate and tiotropium bromide versus individual components in
moderate to severe COPD. Thorax 63(7):592–598
4. Hanania NA, Crater GD, Morris AN, Emmett AH, O’Dell DM,
Niewoehner DE (2012) Benefits of adding fluticasone propionate/
salmeterol to tiotropium in moderate to severe COPD. Respir
Med 106(1):91–101
5. Jung KS, Park HY, Park SY et al (2012) Comparison of tio-
tropium plus fluticasone propionate/salmeterol with tiotropium in
COPD: a randomized controlled study. Respir Med 106(3):
382–389
6. Welte T, Miravitlles M, Hernandez P et al (2009) Efficacy and
tolerability of budesonide/formoterol added to tiotropium in
patients with chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 180(8):741–750
7. Aaron SD, Vandemheen KL, Fergusson D et al (2007) Tio-
tropium in combination with placebo, salmeterol, or fluticasone-
salmeterol for treatment of chronic obstructive pulmonary dis-
ease: a randomized trial. Ann Intern Med 146(8):545–555
8. Cazzola M, Ando F, Santus P et al (2007) A pilot study to assess
the effects of combining fluticasone propionate/salmeterol and
tiotropium on the airflow obstruction of patients with severe-to-
very severe COPD. Pulm Pharmacol Ther 20(5):556–561
9. Williamson PA, Short PM, Clearie KL et al (2010) Paradoxical
trough effects of triple therapy with budesonide/formoterol and
tiotropium bromide on pulmonary function outcomes in COPD.
Chest 138(3):595–604
10. Frith PA, Thompson PJ, Ratnavadivel R et al (2015) Glycopy-
rronium once-daily significantly improves lung function and
health status when combined with salmeterol/fluticasone in
patients with COPD: the GLISTEN study-a randomised con-
trolled trial. Thorax 70(6):519–527
11. Fuhr R, Magnussen H, Sarem K et al (2012) Efficacy of acli-
dinium bromide 400 lg twice daily compared with placebo and
tiotropium in patients with moderate to severe COPD. Chest
141(3):745–752
12. Beier J, Kirsten AM, Mroz R et al (2013) Efficacy and safety of
aclidinium bromide compared with placebo and tiotropium in
patients with moderate-to-severe chronic obstructive pulmonary
disease: results from a 6-week, randomized, controlled Phase IIIb
study. COPD 10(4):511–522
13. Williamson PA, Clearie K, Menzies D, Vaidyanathan S, Lip-
worth BJ (2011) Assessment of small-airways disease using
alveolar nitric oxide and impulse oscillometry in asthma and
COPD. Lung 189(2):121–129
14. Anderson WJ, Lipworth BJ (2012) Relationships between
impulse oscillometry, spirometry and dyspnoea in COPD. J R
Coll Physicians Edinb 42(2):111–115
15. Crim C, Celli B, Edwards LD et al (2011) Respiratory system
impedance with impulse oscillometry in healthy and COPD
subjects: ECLIPSE baseline results. Respir Med 105(7):
1069–1078
16. Cazzola M, MacNee W, Martinez FJ et al (2008) Outcomes for
COPD pharmacological trials: from lung function to biomarkers.
Eur Respir J 31(2):416–469
17. Short PM, Williamson PA, Elder DH, Lipworth SI, Schembri S,
Lipworth BJ (2012) The impact of tiotropium on mortality and
exacerbations when added to inhaled corticosteroids and long-
acting beta-agonist therapy in COPD. Chest 141(1):81–86
18. Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT,
McDonald CF (2010) Updating the minimal important difference
for six-minute walk distance in patients with chronic obstructive
pulmonary disease. Arch Phys Med Rehabil 91(2):221–225
19. Puhan MA, Chandra D, Mosenifar Z et al (2011) The minimal
important difference of exercise tests in severe COPD. Eur Respir
J 37(4):784–790
20. Witek TJ Jr, Mahler DA (2003) Minimal important difference of
the transition dyspnoea index in a multinational clinical trial. Eur
Respir J 21(2):267–272
266 Lung (2016) 194:259–266
123
